Moderna and Laboratorios Liomont signed a license, distribution and supply agreement for Mexico’s COVID-19 vaccines, with phased messenger RNA (mRNA) technology transfer, as Mexico’s state-owned BIRMEX awarded Liomont an open contract of US$700 million to US$1.75 billion through 2030.

MANUFACTURING · OCTOBER 31, 2026 · MEXICO
Mexico’s plan to make messenger RNA (mRNA) vaccines at home has moved from a memorandum to contracts. Moderna and Laboratorios Liomont, a private Mexican drugmaker, have signed a license, distribution and supply agreement under which Moderna will manufacture its COVID-19 vaccine for Mexico’s 2026–2027 winter vaccination campaign and Liomont will supply and distribute it to the public sector, while technology is transferred in phases toward local production of both the finished product and the drug substance, according to a statement published by enFarma on October 13.
Separately, state-owned Laboratorios de Biológicos y Reactivos de México (BIRMEX) awarded Liomont, by direct award under the procurement law’s sole-supplier provision (Article 54, fraction I), an open contract for mRNA COVID-19 vaccine worth a minimum of US$700 million and a maximum of US$1.75 billion before taxes, with deliveries from September 13, 2026 through December 31, 2030, according to contract documents reported by El Universal and republished by El Imparcial on October 11. El Imparcial put the ceiling at roughly 31 billion pesos and noted that it is a maximum authorized amount, not money already spent.
US$1.75bn
Ceiling of BIRMEX’s direct award to Liomont for mRNA COVID-19 vaccine, running through December 31, 2030; the minimum is US$700 million, per contract documents reported by El Imparcial.
Both steps follow the memorandum of understanding (MOU) for a five-year strategic agreement that the Mexican government, BIRMEX, Liomont and Moderna signed at Palacio Nacional on February 9, 2026, with President Claudia Sheinbaum, Health Secretary David Kershenobich, Moderna chief executive Stéphane Bancel and Liomont chief executive Alfredo Rimoch present, per El País México. Moderna announced the MOU on February 10, describing it as covering supply of its respiratory vaccine portfolio, technology transfer for local production of its COVID-19 vaccine, joint clinical research and pandemic preparedness. On April 17, 2026, the Secretaría de Salud, BIRMEX, Liomont and Moderna signed an interinstitutional agreement setting out a two-phase plan: local fill-finish first, then production of the mRNA and lipid-nanoparticle drug substance, according to Cadena Política.
What the October agreement settles, and what it does not
For the coming season, the division of labor is clear: Moderna makes the vaccine and Liomont handles supply and distribution in the public market, with an antigenic composition consistent with the World Health Organization’s 2026–2027 recommendation, per enFarma. Román Saglio, who heads Moderna’s commercial operations in Latin America, said the companies aim to ‘contribute to Mexico’s public health infrastructure’; Sergio Valentinotti, Liomont’s director of vaccines and biotechnology, called it ‘an important step toward developing national technological capabilities’ (quotes translated from Spanish).
The communication sets no dates or volumes for the technology transfer. Until local production begins, the vaccine Mexico buys will be made outside the country, and any Liomont facility producing mRNA vaccine would need authorization from the Federal Commission for the Protection against Sanitary Risks (COFEPRIS), the country’s health regulator, before commercial production begins.
A large ceiling with an uncertain volume
The BIRMEX award is an open contract: it fixes a minimum and a maximum, not a delivered quantity. The volume cannot be established from public information. El Universal reported up to 2.5 million vaccines, while the listing on ComprasMX, the federal procurement platform, records one million pieces of a multidose presentation of 10 vials of five doses each, per El Imparcial. The documents cited do not name the manufacturer of the vaccine Liomont will deliver.
The award follows a different channel from last season’s. When Moderna announced the MOU in February, the government had already adjudicated up to 10 million doses of Moderna’s 2025–2026 COVID-19 vaccine, approved by COFEPRIS, to Logística y Transporte para la Industria de la Salud (Medistik), a private health-logistics company that is part of Grupo Traxión, according to Moderna’s release. The new contract makes Liomont a contracted supplier to the public sector through 2030.
Plan Mexico and the outside pressure on mRNA funding
The Moderna–Liomont partnership was signed under Plan Mexico, the government’s industrial-policy programme to increase investment and local production capacity, including medicines. On May 28, Liomont was one of eight companies — with Abbott, Bristol Myers Squibb, Grupo Neolpharma, Laboratorios Kener, Sanofi, Bayer and Opella — that announced investments of more than 21 billion pesos in Mexico, per El País México and El CEO.
The United States offers a contrast. Food and Drug Administration (FDA) Commissioner Marty Makary said on February 23 that the agency supports mRNA vaccines but that US taxpayers should not bear the cost of mRNA research, explaining the Department of Health and Human Services (HHS) shift of funds after it cancelled 22 mRNA contracts worth about US$500 million in August 2025, according to Reuters and BioSpace. A government that commits to buy, as Mexico has, may become a more attractive partner for mRNA developers facing reduced public funding in the US.
What to Watch
- How many doses BIRMEX actually draws under the US$700 million to US$1.75 billion open contract with Liomont, starting with the 2026–2027 winter campaign
- A timetable for the phased technology transfer, and COFEPRIS inspection of any Liomont site designated for mRNA finished product or drug substance
- Whether the joint clinical research foreseen in the February MOU produces registered studies in Mexico
The contracts give Liomont a contracted public-sector channel before it makes a single dose locally. Whether that becomes domestic mRNA capacity depends on a transfer schedule that the companies have not formally published.
Moderna, Liomont and BIRMEX: Timeline
MOU signed
2026-02-09
The Mexican government, BIRMEX, Liomont and Moderna sign an MOU toward a five-year agreement on vaccine supply, technology transfer, joint research and pandemic preparedness; Moderna announces it on February 10.
Interinstitutional agreement
2026-04-17
Secretaría de Salud, BIRMEX, Liomont and Moderna formalize a two-phase plan (fill-finish, then mRNA and lipid-nanoparticle drug substance).
BIRMEX direct award
2026-09-06
BIRMEX notifies Liomont of a direct award for mRNA COVID-19 vaccine, worth US$700 million to US$1.75 billion, with deliveries from September 13, 2026 to December 31, 2030.
License, distribution and supply agreement
2026-10-13
Moderna and Liomont announce the agreement: Moderna manufactures for the 2026–2027 season, Liomont supplies and distributes, and technology is transferred in phases.
Sources: El País México (2026-02-10); Moderna press release (2026-02-10); Cadena Política (2026-04-17); El Imparcial, citing El Universal and ComprasMX (2026-10-11); enFarma (2026-10-13)
Why this is relevant
Patients
The agreement secures a supplier of COVID-19 vaccine for Mexico’s public 2026–2027 winter campaign.
Industry
Liomont gains a public-sector contract of up to US$1.75 billion through 2030 and a licensing relationship with Moderna, a position that could shape future vaccine tenders in Mexico. Competing suppliers face a market in which the state has already committed a multi-year channel.
Payers
BIRMEX has committed a minimum of US$700 million through 2030 without a competitive tender; the actual cost will depend on how many doses it orders each season, which public documents do not yet make clear.
Regulators
COFEPRIS authorization of any Liomont facility for mRNA production would be required before local manufacturing can begin, making its capacity and timing a constraint on the technology transfer.
Sources: enFarma: Moderna y Laboratorios Liomont apoyan suministro de vacunas contra COVID-19 en México · El Imparcial: Birmex adjudica directamente a Laboratorios Liomont un contrato de hasta 31 mil millones de pesos · El Universal: Birmex adquiere 2.5 millones de vacunas covid por 31 mil mdp · Moderna: Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico · El País México: México firma un acuerdo con la estadounidense Moderna · Cadena Política: Birmex, Liomont y Moderna, producción de vacunas en México · El País México: El sector farmacéutico anuncia inversiones por 21.000 millones de pesos · El CEO: Bayer, Sanofi y otras farmacéuticas anuncian inversión de 21,000 mdp en México · Reuters: US FDA Commissioner Makary says FDA supports mRNA vaccines · BioSpace: FDA’s Makary backs mRNA vaccines but says companies can fund their own research
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.







